Don’t Trade in the Dark—Get Your Pre-Market Report Every Day.Join Now
Search stocks
Laurus Labs Ltd

| Q4 FY26 Earnings Conference Call

BULLISH SENTIMENT

Report Source

⬤5th May 26

Summary : Laurus Labs reports strong FY26 performance driven by CDMO growth and capacity expansion, with a positive outlook for continued strategic transformation.

Management Perspective positive : Management repeatedly expresses confidence in growth, maintaining margins, and the robustness of their pipeline. Phrases like 'momentum is building,' 'very confident,' and 'robust operational execution' are used.

Concall Report Analysis & Insights

Business Overview

  1. Company significantly accelerated performance in FY26 due to sustained demand.
  2. Portfolio transformation is underway, with momentum building on strategy execution.
  3. Exceeded 8,200 cubic meters of reactor volume for small molecule, API, and intermediate manufacturing.
  4. CDMO business grew significantly, now contributing over 30% of revenue.
  5. Maintained global leadership in anti-retroviral therapy, servicing one-third of the HIV population.

Future Growth Prospects

  1. Unit 7 greenfield project will have first production ready by March '27, with 2,000 cubic meters additional reactor volume.
  2. Commercial scale peptide manufacturing block ready for validation in Q2 FY27.
  3. Fermentation greenfield site for Laurus Bio Phase 1 will start by end of 2026.
  4. Formulation facility under KRKA joint venture Phase 1 to be completed by mid-2027.
  5. Expect to maintain or improve EBITDA margins in FY27, with operational leverage contributing.

Management Insights

  1. "Our company's purpose of chemistry for better living guides everything what we do."
  2. "The transformation of our portfolio is well underway. The momentum is building."
  3. "We are very confident on maintaining or improving this EBITDA margin in FY '27."
  4. "We are a strategic partner for many big pharma right now. So we have a robust pipeline."
  5. "Most of the capex what we're doing is growth capex. We have visibility."

Signs of Skepticism

  1. Management declined to provide specific quantitative guidance on future growth percentages for certain segments.
  2. Specific details on capex allocation for peptide capacity were not disclosed.
  3. Customer advances on the balance sheet were not disclosed.
  4. Management did not comment on specific customer-related topics due to confidentiality.

Risk Factors

  1. Increasing geopolitical disruptions may impact raw material availability and logistics.
  2. Potential for quarter-on-quarter lumpiness in CDMO segment earnings.
  3. Solvent price increases could put pressure on operating costs.
  4. Uncertainty in commercialization timelines for late-stage clinical programs.

Good To Know

  1. R&D spending for FY26 was 4.1% of sales, including cell and gene therapy space.
  2. Company passed 132 quality audits by regulatory agencies and customers without critical findings.
  3. Net debt stood at INR2,285 crores, with debt by EBITDA at 1.25x.
  4. ARV revenue contribution decreased from 67% to 41% of total revenue.
  5. AI is leveraged in discovery space globally, but Laurus is not involved in discovery for partners.

Key Drivers

  1. New manufacturing unit 7 coming online.
  2. Peptide manufacturing block for commercial validation.
  3. Laurus Bio fermentation site operational by 2026.
  4. Strong CDMO pipeline converting to commercial.

Key Analyst Discussions

Competitive Environment

  1. Laurus is considered a strategic partner for big pharma, not tactical.
  2. Company is well de-risked from product concentration risk in CDMO.
  3. Focus on advanced intermediates or APIs for longer sustainability of offerings.
  4. Not involved in the discovery side of things for partners, minimizing AI impact on their operations.

Market Trends & Consumer Behavior

  1. Underlying demand momentum for complex APIs remains strong.
  2. Company is exploring opportunities in the weight loss sector within peptides.
  3. Global rating agencies recognize the company's EHS/ESG initiatives.
  4. Big pharma increasingly demands validation and engineering batches at commercial scale.

Financial Highlights

  1. EBITDA margin improved to 26.8% for FY26, with Q4 at 28.9%.
  2. ROCE improved to 17.7% from 9.7% in the previous year.
  3. Capex guidance for the next two years is INR3,000 crores.
  4. Gross margins are expected to remain similar between development and commercial phases.
  5. Gross debt may slightly increase in FY27, but debt-to-EBITDA ratio will be maintained or softened.

Product Composition

  1. CDMO business grew 38% to INR2,080 crores, driven by late-stage pipeline and NCE API supplies.
  2. Affordable Medicines (Generics) division delivered INR4,733 crores, an 18% growth.
  3. Laurus Bio division reported Q4 sales of INR65 crores, with full-year sales up 15%.
  4. ARV business is roughly two-thirds API and one-third formulations.
  5. Non-ARV formulation business is growing, with momentum expected to sustain.

Strategic Considerations

  1. Investing in high-growth modalities, large-scale manufacturing, and important technologies.
  2. Expanding fermentation capacity to 2 million liters in a phased manner.
  3. Investing in gene therapy and ADC manufacturing facilities in Hyderabad.
  4. Aiming for CDMO revenues to reach 50% of overall sales by 2030.
  5. Focusing on product complexity, scale, and sustainable technology platforms.
Laurus Labs Ltd (LAURUSLABS) Concall Report Analysis & Insights | Dhanarthi